KNSA Stock Price Chart
KNSA Earnings
Kiniksa Pharmaceuticals International PLC
$77.83
-0.4%
$-0.32
At close: Aug 13, 16:00:00 GMT-4
$79.39
2%
$1.56
Post-market: Aug 13, 20:00:00 GMT-4
Back
Kiniksa Pharmaceuticals International PLC (KNSA) Earnings
Key Stats
Prev.Close
$78.15
Open
$78.33
Day's Range
$77.19 - $79.69
52 week range
$31.78 - $82.94
Volume
451.3K
Avg.Volume
778.6K
Dividend yield
--
EPS (TTM)
0.98
Market Cap
$6.1B
What is KNSA?
Kiniksa Pharmaceuticals International Plc is a commercial-stage biopharmaceutical company. Its portfolio of immune-modulating assets, ARCALYST, abiprubart and mavrilimumab, is based on strong biologic rationale or validated mechanisms, targets a spectrum of underserved cardiovascular and autoimmune conditions and offers the potential for differentiation. ARCALYST is an interleukin-1α and interleukin-1β cytokine trap. ARCALYST is used for the treatment of recurrent pericarditis and reduction in risk of recurrence in adults and children 12 years and older. ARCALYST is also approved for the treatment of Cryopyrin-Associated Periodic Syndromes (CAPS), including Familial Cold Autoinflammatory Syndrome (FCAS) and Muckle-Wells Syndrome, and the maintenance of remission in Deficiency of Interleukin-1 Receptor Antagonist.
